Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-NETU vs fosaprepitant for prevention of CINV in AC/EC chemotherapy
jRCT2080224620Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosnetupitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Started Mar 2019; status: completed.
02
Drugs
fosnetupitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on jRCT2080224620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224620.